UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                       SEC File Number: 33-51218
                                                       CUSIP Number: 817259104

(Check  one):  [X] Form  10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q
               [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR

         For Period Ended: February 28, 2009

         [ ]  Transition Report on Form 10-K
         [ ]  Transition Report on Form 20-F
         [ ]  Transition Report on Form 11-K
         [ ]  Transition Report on Form 10-Q
         [ ]  Transition Report on Form N-SAR
         For the Transition Period Ended: __________________

Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

- --------------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION

SensiVida Medical Technologies, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant

Mediscience Technology Corporation
- --------------------------------------------------------------------------------
Former Name if Applicable

77 Ridgeland Road
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

Henrietta, NY 14623
- --------------------------------------------------------------------------------
City, State and Zip Code

PART II -- RULES 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate.)

         (a)      The reasons described in reasonable detail in Part III of this
                  form could not be eliminated without unreasonable effort or
                  expense;

[X]      (b)      The subject annual report, semi-annual report, transition
                  report on Form 10-K, Form 20-F,11-K Form N-SAR or Form N-CSR,
                  or portion thereof, will be filed on or before the fifteenth
                  calendar day following the prescribed due date; or the subject
                  quarterly report or transition report on Form 10-Q, or portion
                  thereof will be filed on or before the fifth calendar day
                  following the prescribed due date; and

         (c)      The accountant's statement or other exhibit required by Rule
                  12b-25(c) has been attached if applicable.





PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed time period.

         The Registrant cannot file its Annual Report on Form 10-K for the year
ended February 28, 2009 within the prescribed time period because of delays in
completing the preparation of its audited consolidated financial statements and
management's discussion and analysis.

PART IV -- OTHER INFORMATION

(1)    Name and telephone number of person to contact in regard to this
notification.

         Kamal Sarbadhikari               585                  413-9080
- --------------------------------------------------------------------------------
         (Name)                       (Area Code)         (Telephone Number)

(2)    Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
                                                                  [X] Yes [ ] No


(3)  Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
                                                                  [ ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

- --------------------------------------------------------------------------------

                      SENSIVIDA MEDICAL TECHNOLOGIES, INC.
                  (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.



Date: May 28, 2009                          By:   /s/ Kamal Sarbadhikari
                                                  -----------------------------
                                                  Kamal Sarbadhikari
                                                  President and CEO


                                       2